Semaphorin 7A Antibody (310829) [Alexa Fluor™ Plus 405]

• Reactivity: Hu
• Clone: 310829
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor Plus 405

Semaphorin 7A Antibody (310829) [Alexa Fluor™ Plus 405] Summary

• Specificity: Detects human Semaphorin 7A in direct ELISAs.
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Semaphorin 7A Antibody (310829) [Alexa Fluor™ Plus 405]

• CD108 antigen
• CD108
• CD108MGC126696
• CDw108
• H-SEMA-K1
• H-Sema-L
• JMH blood group antigen
• JMH
• John-Milton-Hargen human blood group Ag
• MGC126692
• sema domain, immunoglobulin domain (Ig), and GPI membrane anchor, (semaphorin)7A (JMH blood group)
• sema domain, immunoglobulin domain (Ig), and GPI membrane anchor, (semaphorin)7A
• sema domain, immunoglobulin domain (Ig), and GPI membrane anchor, 7A
• Sema K1
• Sema L
• Sema7A
• SEMAK1
• SEMAL
• SEMALJohn Milton Hagen blood group H-Sema K1
• Semaphorin 7A
• semaphorin 7A, GPI membrane anchor (John Milton Hagen blood group)
• semaphorin K1
• semaphorin L
• semaphorin-7A
• semaphorin-K1
• semaphorin-L

Background

Semaphorin 7A (Sema7A, designated CD108, previously Sema K1 or Sema L), is an ~80 kDa membrane-anchored glycoprotein that is a member of the Semaphorin family of axon guidance molecules (1‑4). On human erythrocytes, it is the John Milton Hagen (JMH) blood group antigen (4). Sema7A is the only known Class 7 or glycophosphatidylinositol (GPI)-linked semaphorin; its expression is concentrated in the brain, spleen and thymus (1‑5). Human Sema7A cDNA encodes a 44 amino acid (aa) signal sequence, a 604 aa extracellular domain (ECD) including Sema and C2‑type Ig-like domains, and an 18 aa propeptide/GPI membrane anchor signal sequence. Mature human Sema7A shares 89%, 89%, 88%, 86% and 90% aa identity with mouse, rat, canine, bovine and equine Sema7A, respectively. The Sema7A sema domain contains an RGD integrin interaction motif (4). Although it binds plexin-C1 in vitro and may be coexpressed with it, many of its activities depend on interaction with beta 1 integrins such as alpha 1 beta 1 (6‑10). Sema7A signaling through the two receptors may cause opposing effects (8). Sema7A is an immune semaphorin, with expression and activity on CD4+CD8+ thymocytes, activated T cells, macrophages and microglia (2, 9‑12). T cell Sema7A interacts with monocytic cells, stimulating their chemotaxis, production of pro-inflammatory cytokines, and dendritic differentiation (5, 6). However, on the T cells themselves, Sema7A downregulates TCR signaling by promoting TCR internalization, modulating T cell responses (9). In lung macrophages, Sema7A is induced by TGF-beta and participates in TGF-beta -induced lung fibrosis (12). Sema7A is also expressed on pre-osteoblasts and osteoclasts, where it promotes migration and fusion, respectively; on keratinocytes, where it promotes melanocyte spreading and dendricity; and on some neurons, for example, promoting axon outgrowth in the developing olfactory tract (8, 10, 13). 

1. Yazdani, U. and J.R. Terman (2006) Genome Biol. 7:211.
2. Kikutani, H. et al. (2007) Adv. Immunol. 93:121.
3. Sato, Y. and Takahashi H. (1998) Biochim. Biophys. Acta. 1443:419.
4. Yamada, A. et al. (1999) J. Immunol. 162:4094.
5. Holmes, S. et al. (2002) Scand. J. Immunol. 56:270.
6. Suzuki, K. et al. (2007) Nature 446:680.
7. Pasterkamp, R.J. et al. (2007) BMC Dev. Biol. 7:98.
8. Scott, G.A. et al. (2007) J. Invest. Dermatol. 128:151.
9. Czopik, A.K. et al. (2006) Immunity 24:591.
10. Pasterkamp, R.J. et al. (2003) Nature 424:398.
11. Mine, T. et al. (2000) Tissue Antigens 55:429.
12. Kang, H.-R. et al. (2007) J. Exp. Med. 204:1083.
13. Delorme, G. et al. (2005) Biol. Cell 97:589.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.